Company profile: Pangaea Oncology
1.1 - Company Overview
Company description
- Provider of precision oncology and personalized medicine based on genetic analysis for cancer patients, offering molecular diagnostics across cancer types, clinical trials services, biomarker discovery, companion diagnostics (DX) platform validation, preclinical research and diagnostics, in-vitro drug/vaccine testing, and multiplex assays in non-blood biological fluids for diagnostic and predictive value.
Products and services
- Biomarker Discovery: Architects research-grade programs to identify cancer-involved genes, enabling development of novel molecular diagnostic tools and improved patient care through biomarkers
- DX Platforms Validation: Delivers companion-diagnostic-focused molecular tests that identify patients most likely to benefit from specific treatments, supporting platform validation for precision oncology applications
- Molecular Diagnostics: Engineers genomics-driven assays that detect genetic alterations in tumors across all cancer types to personalize therapy decisions for cancer patients through targeted genetic analysis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pangaea Oncology
Celmatix
HQ: United States
Website
- Description: Provider of preclinical discovery and development focused on women’s ovarian health, including target identification and validation for endometriosis, PCOS, and ovarian senescence; collaborative discovery, development, and commercialization with Evotec and Bayer; contraceptive target discovery supported by the Bill & Melinda Gates Foundation; and proprietary cohorts, annotations, and NLP-driven research tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celmatix company profile →
Chimerix
HQ: United States
Website
- Description: Provider of antiviral and oncology therapeutics, developing CMX001 as a potential broad‑spectrum antiviral for life‑threatening double‑stranded DNA. Programs include ONC201 for H3 K27M‑mutant glioma, ONC206 for recurrent and rare CNS cancers, and ONC212 with preclinical activity in solid tumors and hematologic malignancies. Runs the Phase 3 ACTION study of ONC201 and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chimerix company profile →
CGC Genetics
HQ: Portugal
Website
- Description: Provider of medical genetics services with great technological capacity in clinical genomics, molecular diagnostics, cytogenetics, prenatal screening, and pathology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CGC Genetics company profile →
GreenLight Biosciences
HQ: United States
Website
- Description: Provider of RNA-based solutions for agriculture and human health, offering a proprietary platform to produce RNA at scale cost-effectively and products targeting pests and diseases without harming beneficial insects, including Varroa mite control for honeybees and Calantha, an EPA-approved RNA product for Colorado Potato Beetle control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GreenLight Biosciences company profile →
Diagnoplex
HQ: Switzerland
Website
- Description: Provider of non-invasive colorectal cancer screening tests and diagnostics, including the COLOX colorectal cancer screening test; the company has conducted a 140-patient prospective pilot study demonstrating technical and clinical feasibility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnoplex company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pangaea Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pangaea Oncology
2.2 - Growth funds investing in similar companies to Pangaea Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pangaea Oncology
4.2 - Public trading comparable groups for Pangaea Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →